Why switch from protease inhibitors (PI) to non-nucleoside reverse transcriptase inhibitors (NNRT1)?

HIV Medicine

Volumn 1, Issue SUPPL. 1, 2000, Pages 7-10

  Pozniak, A L ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HIV AGENTS; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DRUG COMBINATION; DRUG EFFECT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PHYSIOLOGY; REVIEW; TREATMENT OUTCOME; VIROLOGY;

ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMAN; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT OUTCOME;

EID: 18744433652     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1468-1293.2000.00006.x     Document Type: Article

References (18)

1. Bartlett J, Demasi R, Quinn J, Moxham, C, Rousseau F. Metaanalysis of efficacy of triple combination therapy in antiretroviral-naive HIV-1-infected adults. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 519.
2. BHIVA Writing Committee on behalf of the British HIV Association (BHIVA). BHIVA guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 1: 76-101.
3. Carpenter CCJ, Cooper DA, Fischl MA, eraJ. Antiretroviral therapy in adults. Updated recommendations of the International AIDS Society-USA Panel. JAMA 2000; 283: 381-390.
4. Staszewski S, Morales-Ramirez JO, Godofsky EVV, et al. Longer time-to-treatment failure and durability of response with efavirenz + ZDV + 3TC. First analysis of full 1266 patient cohort from study 006. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999; abstract 507.
5. Munoz V, Casado JL, Moreno A, Dronda F, era!. Persistent viral suppression after switching a protease inhibitor (Pl)-containing regimen to a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based therapy (BEGIN Study). 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999; abstract 2195.
6. Dieleman JP, Gyssens 1C, Sturkienboom MC, et al. Substituting nevirapine for protease inhibitors because of intolerance. 7th European Conference of Clinical Aspects and Treatment of HIV-Infection, Lisbon, October 23-27, 1999; abstract 500.
7. Moyle G, Baldwin C, Dent N, etal. Management of protease inhibitor (Pl)-associated lipodystrophy by substitution with efavirenz (EFV) in virologically controlled HIV-infected persons. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999; abstract 1-2064.
8. Barreiro P, Soriano V, Blanco F, Casimiro C. Risks and benefits of replacing protease inhibitors by nevirapine in patients with long-term successful triple combinations. 7th Conference on Retrovinises and Opportunistic Infections, San Francisco, 2000; abstract 538.
9. Ruiz L, Negredo E, Domingo P, Bonjoch A. clinical, virological, and immunological benefit of switching the protease inhibitor (PI) by nevirapine (NVP) in HAART-experienced patients suffering lipodystrophy (LD): 36-week follow-up. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 206.
10. Rafft F, Bonnet B, Esnault JL, etal. Switch from PI to once daily NNRTI in rlfV-infected patients maintaining undetectable plasma viral loads on Pi-containing regimens: the Maintavir Study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, September 26-29, 1999; abstract 2198.
11. Tebas P, Yarasheski K, Powderly WG, eraJ. Prospective open label pilot trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months. 7th Conference on Retroi'iruses and Opportunistic Infections, San Francisco, 2000; abstract 45.
12. Podzamczer D, Ferrer E, Consiglio E, Gatell JM. Preliminary results of a randomized multicenter study comparing combivir (ZDV/3TC) plus nelfmavir or nevirapine in HIV-infected naive patients (COMBINE Study). 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, 2000; abstract 510.
13. Baker R, Gazzard B, Nelson M. Comparison of combination antiretroviral chemotherapy in patients with low initial CD4 counts. 6th Annual Conference of the British HIV Association (BHIVA), Edinburgh, March 2000; abstract P18.
14. Bower M, Fox P, Fife K, et al. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma. AIDS 1999; 13: 2105-2111.
15. Sullivan K, Nelson M, Moyle G, eraJ. Immune responses in patients changing from PI to NNRTI based HAART. 6th Annual Conference of the British HIV Association (BHIVA), Edinburgh, March 2000; abstract P43.
16. Tashima K, Stryker R, Skiest D, et at. Lipid profiles and clinical lipodystrophy in study 006 patients. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 26-29 September, 1999; abstract 1304.
17. Tashima K, Cu-Uvin S, Caliendo A, Böse T. Suppression of viral load in the female genital tract and cerebrospinal fluid (CSF) in patients on combination therapy including efavircnz. 9th European Conference of Clinical Microbiology and Infectious Diseases, 1999; abstract P0554.
18. Dybul M, ChunTW, WardDJ, et al. Evaluation of lymph node viral burden in HIV-infected individuals receiving an efavirenz-based protease-inhibitor sparing HAART regimen. 39th Interscience Conferenceon Antimicrobial Agentsand Chemotherapy, San Francisco, 26-29 September, 1999; abstract LB1.